A Phase I Study of AMG 757 for Patients with Recurrent or Persistent Small Cell Lung Cancer

Print

Full Title

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer

Purpose

The purpose of this study is to find the highest dose of the investigational drug AMG 757 that can be given in patients with small cell lung cancer that came back or continued to grow despite standard treatment. AMG 757 is a protein that is designed to link the body’s natural cancer-fighting immune cells by attaching to DLL3, a protein on the surface of small cell lung cancer cells. This drug can potentially trigger the immune system to target and kill cancer cells. AMG 757 is given intravenously (by vein) once every 2 weeks.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have small cell lung cancer that came back or continued to grow despite platinum-based chemotherapy.
  • Patients may also participate if they had no more than six cycles of initial platinum-based chemotherapy and are showing a benefit from this treatment, with the last dose given at least 4 weeks before entering the study.
  • Patients should recover from the serious side effects of prior treatments before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Victoria Lai at 646-449-1983.

Protocol

19-198

Phase

I

Investigator

Co-Investigators